Rheumatoid Arthritis News

If you have shoulder pain that affects your daily activities and recreation and is getting progressively worse, you may have developed arthritis.

June 30, 2009 -- Scientists have found a potential new target for rheumatoid arthritis treatment .

A UK survey of 575 rheumatoid arthritis sufferers highlights the importance of maintaining independence and the significant impact that early diagnosis and treatment can have.

What's the difference between rheumatoid and osteoarthritis? When you think of arthritis, you probably picture joints that start aching as you get older and worsen thanks to excess weight or lack of physical activity .

Though Abbott Laboratories lost a nearly $1.7 billion patent verdict for a blockbuster drug, analysts expect Abbott to negotiate an agreement with court victor Johnson & Johnson that would allow both companies to derive benefits from each other's drugs.

Arthritis literally means "Inflammation of Joint", there are various types of arthritis, most common are Osteoarthritis and Rheumatoid Arthritis.

Treatment with anti-tumor necrosis factor agents is recognized as a risk factor for tuberculosis in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis.

Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.

June 29, 2009 -- An experimental drug called masitinib may ease rheumatoid arthritis symptoms in people who aren't helped by other drugs, a new study shows.

The immunosuppressive drug golimumab shows promise in treating rheumatoid arthritis patients who don't respond to other drugs, according to a new study.

Golimumab, a new tumour necrosis factor-I inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-I inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-I inhibitors, finds an Article published Online first and in this week's edition ...

A signal molecule made by the human body that triggers the immune system into action may be important in rheumatoid arthritis, according to new research published today in Nature Medicine .

A clinical trial of masitinib, a drug in development for the treatment of rheumatoid arthritis, has shown it to be well tolerated and effective.

A clinical trial of masitinib, a drug in development for the treatment of rheumatoid arthritis, has shown it to be well tolerated and effective.

A new drug to treat rheumatoid arthritis reduces joint inflammation in severe cases while causing only mild to moderate side effects, according to a report from the first clinical trial of the drug on humans.

Main Category: Arthritis / Rheumatology Also Included In: Regulatory Affairs / Drug Approvals Article Date: 26 Jun 2009 UCB announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending that the European Commission grants a marketing authorisation for Cimzia , in ...

Main Category: Respiratory / Asthma Also Included In: Clinical Trials / Drug Trials Article Date: 25 Jun 2009 Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that it has initiated the first human clinical trial evaluating an oral resolvin therapeutic, RX-10001, in a Phase I clinical trial in healthy ...

Tonia Odom, a 35-year-old patient with rheumatoid arthritis, a sick father and a young son, each of whom has multiple health problems, has found some relief to the problems of managing her families' array of illnesses in at a Duke University clinic that's a model of the "medical home" approach to medicine, the New York Times reports.

GlaxoSmithKline P.L.C. signed a deal yesterday to develop drugs to treat rheumatoid arthritis and other inflammatory diseases.

Main Category: Arthritis / Rheumatology Also Included In: Clinical Trials / Drug Trials Article Date: 23 Jun 2009 - 5:00 PDT printer friendly view / write opinions rate article Neovacs, a biotechnology company developing proprietary immunotherapeutics for autoimmune and chronic diseases, announced that subject to regulatory consent, it plans to ...